m-Maleimidobenzoyl-n-hydroxysuccinimide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: m-Maleimidobenzoyl-n-hydroxysuccinimide
• 英文别名: 1-[3-(1-hydroxy-2,5-dioxopyrrolidine-3-carbonyl)phenyl]pyrrole-2,5-dione
• 化学式: C₁₅H₁₀N₂O₆
• 分子量: 314.25
• InChiKey: WAAXYLYXYLKHJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  m-Maleimidobenzoyl-n-hydroxysuccinimide 、 、 1-[4-(1-Hydroxy-2,5-dioxopyrrolidine-3-carbonyl)phenyl]pyrrole-2,5-dione 、 、 、 sodium sulfosuccinimidyl[4-iodoacetyl]aminobenzoate 、 N-(P-马来酰亚胺基苯基)异氰酸酯 生成 6-[[4-(N-马来酰亚胺甲基)环己基]甲酰氨基]己酸琥珀酰亚胺酯
  参考文献：
  名称：

  Polymer Support

  摘要：

  本发明提供了一种聚合物支撑，其特征在于聚合物是6-氨基6-脱氧壳聚糖。此外，还提供了金属固定的6-氨基6-脱氧壳聚糖，更具体地包括Pd、Pt、Ru、Rh、Ir、Os、Mn、Ni、Co和Fe中的一种或多种，它们的所有可能的氧化态通过席夫碱配体络合到6-氨基6-脱氧壳聚糖上。

  公开号：

  US20120178916A1

文献信息

• [EN] BIOMOLECULE CONJUGATES<br/>[FR] CONJUGUÉS DE BIOMOLÉCULE
  申请人：CELGENE CORP

  公开号：WO2016090157A1

  公开（公告）日：2016-06-09

  The present invention relates to biomolecule conjugates which comprise a biomolecule wherein at least one non-natural amino acid (NNAA) is integral to the structure of the biomolecule and wherein the NNAA is a point of attachment of a linker to which a payload, particularly a cytotoxic agent, is attached. More specifically, this invention relates to conjugates of cell-binding agents and active release products comprising cytotoxic agents wherein the conjugates are produced by means of a cycloaddition reaction. Methods of production, pharmaceutical compositions and methods of use are provided.

  本发明涉及生物分子共轭物，其包括一种生物分子，其中至少有一种非天然氨基酸（NNAA）构成生物分子的结构，并且NNAA是连接物的附着点，连接物上附着有一种荷载物，特别是细胞毒性药剂。更具体地说，本发明涉及细胞结合剂和活性释放产物的共轭物，其中共轭物是通过环加成反应制备的。提供了生产方法、药物组合物和使用方法。
• Haptens, immunogens, antibodies and conjugates to 2-oxo-3-hydroxy-LSD
  申请人：——

  公开号：US20030143655A1

  公开（公告）日：2003-07-31

  The invention provides a hapten derivatised with a crosslinker at the nitrogen of the 8&bgr;-carboxamide of 2-oxo-3-hydroxy LSD. The invention also provides an immunogen comprising the aforementioned hapten coupled to an antigenicity-conferring carrier material; a conjugate comprising the aforementioned hapten coupled to a labelling agent, as well as, antibodies raised against the aforementioned immunogen and capable of binding with at least the 3-hydroxy-2-pyrrolidone structural epitope of 2-oxo-3-hydroxy LSD.

  该发明提供了一种在2-氧-3-羟基LSD的8&bgr;-羧酰胺的氮原子上与交联剂衍生的半抗原。该发明还提供了一种免疫原，包括上述半抗原偶联到具有抗原性的载体材料；一种包括上述半抗原与标记剂偶联的结合物，以及针对上述免疫原产生的并且能够与至少2-氧-3-羟基LSD的3-羟基-2-吡咯烷酮结构表位结合的抗体。
• Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
  申请人：Steeves Rita

  公开号：US20050169933A1

  公开（公告）日：2005-08-04

  The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.

  本发明揭示了一种将马替西酮靶向到选定细胞群体的方法，该方法包括将怀疑含有所选细胞群体的细胞群体或组织与细胞结合剂马替西酮结合物接触，其中一个或多个马替西酮通过不可切割的连接剂与细胞结合剂共价结合，并且细胞结合剂与所选细胞群体的细胞结合。
• PLATINUM-ACRIDINE COMPOUNDS AND METHODS OF TREATING CANCERS
  申请人：Wake Forest University

  公开号：US20210330679A1

  公开（公告）日：2021-10-28

  Platinum-acridines and analogs thereof as cytotoxic agents for cancer treatment. Also provided methods of using hMATE1 (SLC47A1) as a biomarker to identify tumors that are likely to respond to the agents, and epigenetically sensitizing tumor tissue to anticancer drugs targeting this membrane transporter.

  铂金-花菁和其类似物作为抗癌细胞毒剂。还提供了使用hMATE1（SLC47A1）作为生物标志物来识别可能对这些药物产生反应的肿瘤的方法，并通过表观遗传学使肿瘤组织对靶向该膜转运体的抗癌药物敏感化。
• Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs
  申请人：Randox Laboratories Limited

  公开号：US20030170728A1

  公开（公告）日：2003-09-11

  The invention provides an immunogen comprising a hapten coupled to an antigenicity-conferring carrier material, a conjugate comprising the aforementioned hapten coupled to a labelling agent, as well as, antibodies raised against the aforementioned immunogen and capable of binding with at least one structural epitope of metabolites of fentanyl and of metabolites of fentanyl analogs.

  该发明提供了一种免疫原，其中包括一个与赋予抗原性载体材料偶联的半抗原，以及一个包括前述半抗原与标记剂偶联的结合物，还提供了针对前述免疫原产生的抗体，这些抗体能够结合芬太尼代谢物和芬太尼类似物代谢物的至少一个结构表位。